TYRP1 and neoplasm: Only pre-conditioning with radiation (46) or in the case of B16/F10, pretreating the tumor with an anti-TRP1 antibody in combination with further CAR-T cell enhancements, makes these tumors responsive to CAR-T cells therapy (47).